References
- 1. Cheson B et al. Monoclonal Antibody Therapy for B-Cell Non-Hodgkin’s Lymphoma. New England Journal of Medicine. 2008; 359:613-626.
- 2. Menon MP, Pittaluga S, Jaffe ES. The Histological and Biological Spectrum of Diffuse Large B-cell Lymphoma in the WHO Classification. Cancer J. 2012 September; 18(5):411–420.10.1097/PPO.0b013e31826aee97
- 3. Kwak JY. Treatment of Diffuse Large B Cell Lymphoma. Korean J Intern Med. 2012; 27:369-377.10.3904/kjim.2012.27.4.369
- 4. Ruzek KA, Wenger DE. The multiple faces of lymphoma of the musculoskeletal system. Skeletal Radiol. 2004; 33:1–8.10.1007/s00256-003-0709-y
- 5. Caporale MF et al. Non-Hodgkin’s lymphoma: unexpected cause of shoulder pain. A systematic review of the literature. Muscles, Ligaments, and Tendons Journal. 2013; 3(3):236-239.
- 6. Baar J, Burkes RL, Gospodarowicz M. Primary non-Hodgkin's lymphoma of bone. Semin Oncol. 1999 Jun; 26(3):270-275.
- 7. Engels EA. Infectious Agents as Causes of Non-Hodgkin Lymphoma. Cancer Epidemiol Biomarkers Prev. 2007; 16:401-404.10.1158/1055-9965.EPI-06-1056
- 8. Zhang Y et al. Ultraviolet radiation exposure and risk of non-Hodgkin's lymphoma. Am J Epidemiol. 2007 Jun 1; 165(11):1255-1264.
- 9. Samir D, Chavez J, Castillo JJ, Sokol L. Hepatitis B infection increases the risk of non-Hodgkin lymphoma: A meta-analysis of observational studies. Leukemia Research 37. 2013; 1107–1115.
- 10. Marcucci F, Mele A. Hepatitis viruses and non-Hodgkin lymphoma: epidemiology, mechanisms of tumor-igenesis, and therapeutic opportunities. Blood. 2011; 117(6):1792-1798.
- 11. Yang JD, Girotra M, Vaid A, Duarte-Rojo A. Hepatitis B reactivation in patient with non-Hodgkin's lymphoma receiving rituximab-based chemotherapy: need for education and attention. J Ark Med Soc. 2013 Nov; 110(6):110-2.
- 12. Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs. 2003; 63(8):803-43.
- 13. Dong HJ, Ni LN, Sheng GF, Song HL, Xu JZ, Ling Y. Risk of hepatitis B virus (HBV) reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy: a meta-analysis. J Clin Virol. 2013 Jul; 57(3):209-14.10.1016/j.jcv.2013.03.010
- 14. Lee IC, Huang YH, Chu CJ, Lee PC, Lin HC, Lee SD. Hepatitis B virus reactivation after 23 months of rituximab-based chemotherapy in an HBsAg negative, anti-HBs-positive patient with follicular lymphoma. J Chin Med Assoc. 2010; 73:156–60.
- 15. Davis J. Preventing hepatitis B virus reactivation following immunosuppressive therapy. Intern Med J. 2008; 38:617, author reply 17-18.10.1111/j.1445-5994.2008.01652.x
- 16. Changhong Liu et al. Entecavir and lamivudine therapy for severe acute chronic hepatitis B. Experimental and Therapeutic Medicine. 2013; 5:545-548.